A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
One step forward, two steps back for biotech.
Tough equity markets as well as competitor developments prompt a narrowed focus.
Another SERD catalyst and the son of Darzalex take centre stage.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
